학술논문
1501TiP A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S845-S845
Subject
Language
ISSN
0923-7534